Pyxis Oncology (PYXS) EBITDA (2020 - 2026)

Pyxis Oncology (PYXS) has reported EBITDA for 7 consecutive years, with -$26.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA fell 31.59% year-over-year to -$26.0 million in Q2 2026; TTM through Jun 2026 was -$87.5 million, a 17.83% increase from a year earlier, with the FY2025 full-year figure at -$84.4 million, up 5.63% from the prior year.
• EBITDA was -$26.0 million for Q2 2026 at Pyxis Oncology, down from -$18.3 million in the prior quarter.
• Over five years, EBITDA peaked at -$5.6 million in Q1 2024 and troughed at -$40.1 million in Q4 2024.
• A 5-year average of -$23.9 million and a median of -$23.5 million in 2025 frame the typical range for EBITDA.
• Across the five-year window, EBITDA plunged 333.02% in 2022 and soared 73.25% in 2024, its largest moves.
• Over 5 years, EBITDA stood at -$38.0 million in 2022, then surged by 53.21% to -$17.8 million in 2023, then plunged by 125.52% to -$40.1 million in 2024, then surged by 54.34% to -$18.3 million in 2025, then plunged by 42.06% to -$26.0 million in 2026.
• The last three EBITDA figures came in at -$26.0 million (Q2 2026), -$18.3 million (Q4 2025), and -$23.5 million (Q3 2025), per Business Quant data.